Cadila Healthcare to raise upto Rs 150 crore via bonds

11 Jul 2011 Evaluate

Cadila Healthcare is looking to raise at least Rs 150 crore via 5 years bond with call option after 3 years via book building at a semi-annual coupon of 9.60-9.70 percent. The issue opens and closes today and the bonds have been rated ‘AA+’ by CRISIL. Credit Agricole and SBI Capital Markets are arrangers to the deal.

Recently, Cadila Healthcare had received a warning notice from the US health regulator for violation of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals at its facility in Gujarat. The Gujarat Plant was inspected by USFDA between January 17 and February 3, 2011, and reviewed the firm's response to its observations on February 10, 2011, and noted that it lacks sufficient corrective actions.

Cadila Pharmaceuticals focuses on various areas, such as formulations (human & veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

879.85 11.65 (1.34%)
24-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.50
Dr. Reddys Lab 1201.45
Cipla 1551.30
Lupin 2104.90
Zydus Lifesciences 879.85
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...